Injection Manufacturing Company in India

A DCGI registration confirms that a pharmaceutical facility is legally permitted to manufacture medicines in India under domestic regulations. WHO-GMP certification is a separate, higher-level independent audit conducted against the World Health Organization's Good Manufacturing Practice guidelines and it is the minimum standard required for export to most regulated and semi-regulated markets globally. The practical difference for buyers is significant. A DCGI-registered injection manufacturing company in India can supply the domestic market legally. A WHO-GMP certified one can supply institutional buyers, international NGO procurement programmes, government tenders in Africa and the Middle East, and health organisations including UNICEF and the Global Fund because those procurement bodies require WHO-GMP as a mandatory qualification criterion before a supplier is even considered. 9M India holds WHO-GMP certification specifically covering sterile injectable manufacturing not a generic plant-level certificate. This means the sterile injectable facility at Birkoni has been independently audited and confirmed to meet international GMP standards for aseptic manufacturing, environmental monitoring, quality control systems, and documentation not just domestic registration requirements.

9M India manufactures injectable pharmaceuticals in three container formats and six therapeutic categories from its WHO-GMP certified sterile facility in Birkoni, Chhattisgarh. By container format: Liquid vials (single-dose and multi-dose in 2ml to 100ml fill volumes), glass ampoules (1ml to 10ml hermetically sealed single-dose preparations), and dry powder injections (for molecules requiring reconstitution at point of use including Ceftriaxone, Pantoprazole, and Methylprednisolone). By therapeutic category: Analgesic and pain relief injectables (Paracetamol, Ketorolac, Diclofenac), anaesthetic injectables (Lidocaine, Ropivacaine, Propofol), cardiovascular injectables (Heparin, Labetalol, Adenosine), gastrointestinal injectables (Ondansetron, Pantoprazole, Methylprednisolone), anti-inflammatory injectables (Dexamethasone, Ketorolac), and anti-infective and antibiotic injectables (Ceftriaxone, Amikacin, Gentamicin). All molecules in the portfolio carry valid DCGI product-specific manufacturing licences. A complete product list with molecules, strengths, container formats, and pack sizes is available within 24 hours of request at info@9mindia.in.

Choosing the right injection manufacturing company in India requires evaluating eight criteria before any commercial discussion begins. First, verify WHO-GMP certification and confirm it is facility-specific and covers sterile injectable manufacturing, not a generic company-level document. Second, confirm DCGI product-specific manufacturing licences for every molecule you need a WHO-GMP plant without molecule-specific licences cannot legally supply those products. Third, check whether the facility has in-house sterility and bacterial endotoxin (LAL) testing outsourced QC introduces chain-of-custody gaps that institutional buyers and regulatory authorities do not accept. Fourth, request documentation within a test deadline COA, COC, stability data, and WHO-GMP certificate should be deliverable within 24 hours. Fifth, verify export history active export to regulated or semi-regulated markets is the strongest external validation of real compliance. Sixth, confirm all three injectable container formats are available if you need liquid vials, ampoules, and dry powder from a single supplier. Seventh, check cold chain capability for temperature-sensitive molecules. Eighth, confirm minimum order quantities match your volume requirements. 9M India satisfies all eight criteria. Documentary evidence for each is available on request at info@9mindia.in.

For institutional and government tender submissions in India including CGHS, ESIC, state procurement, and central government programmes a compliant injection manufacturing company in India must provide the following documents, typically within 24 to 48 hours of a tender notification: Certificate of Analysis (COA) from an in-house QC laboratory confirming batch-specific analytical results. Certificate of Conformance (COC) confirming GMP-compliant manufacture. WHO-GMP certificate current, facility-specific, covering the relevant manufacturing category. DCGI manufacturing licence — product-specific Form 25/28 for each molecule being tendered. Stability data conducted to ICH conditions confirming the approved shelf life. Process validation reports from a minimum of three consecutive commercial-scale batches. Site Master File or relevant sections confirming facility details, quality systems, and cleanroom classification. 9M India maintains all of the above in a pre-archived, version-controlled documentation system. The complete tender documentation package is available within 24 hours of request without exception. Contact info@9mindia.in or call +91 9900095000 to initiate a documentation request.

The minimum order quantity for injectable products at 9M India is 1 Lakh (1,00,000) units for domestic supply within India. This MOQ applies across liquid vials, glass ampoules, and dry powder injection formats. For export orders, minimum quantities are discussed on a case-by-case basis depending on the molecule, container format, pack size, destination market, and whether the order is a one-time procurement or part of an ongoing supply agreement. Multi-molecule orders where a buyer sources three or more injectable products simultaneously are accommodated with consolidated batch planning to optimise lead times across the full order. To receive a tailored MOQ, pricing indication, and product availability confirmation for specific molecules, contact the 9M India sales team at info@9mindia.in or +91 9900095000. A focused response covering molecule availability, current batch schedule, and documentation readiness is provided within 24 hours.

Yes. 9M India has active experience supplying injectable pharmaceuticals to government and institutional procurement programmes including CGHS, ESIC, and state government tender authorities across India. All injectable products in the 9M India portfolio are DCGI-approved under product-specific manufacturing licences. The complete institutional tender documentation package — COA, COC, WHO-GMP certificate, DCGI manufacturing licence, stability data, and process validation reports — is pre-prepared and available for bid submission within 24 hours of tender notification. For international institutional procurement — including tenders from NGOs, health ministries, and international health agencies in Africa, the Middle East, and SAARC 9M India's WHO-GMP certification qualifies the facility for participation. Export registration dossiers formatted to the Common Technical Document (CTD) structure are available for target market regulatory submissions. Product availability, batch scheduling, and documentation requirements for specific institutional tenders can be discussed directly with the 9M India regulatory and sales team at info@9mindia.in.

Yes. 9M India operates as a full-service third-party and contract injection manufacturing company in India — manufacturing injectable products under partner brands with complete regulatory, quality, and documentation support from a single WHO-GMP certified facility. Third-party manufacturing at 9M India covers manufacturing under the partner's brand name and product licence, aseptic fill-finish and quality release to partner specifications, COA issued in the partner's product name from 9M India's in-house QC laboratory, and full DCGI Form 25/28 compliance for third-party manufacturing operations. Contract manufacturing covers end-to-end production from formulation development through commercial supply, where 9M India holds the manufacturing licence and the partner holds the marketing authorisation. This model is suitable for pharma companies that want to market injectable products under their own brand without building or operating a sterile manufacturing facility. Both services include dedicated account management, scheduled batch planning, and priority documentation turnaround. Minimum commercial quantity is 1 Lakh units per batch. Multi-product agreements are available for partners sourcing three or more injectable molecules. Enquiries can be submitted at info@9mindia.in or +91 9900095000.

Liquid vials, glass ampoules, and dry powder injections are the three container formats used for Small Volume Parenteral (SVP) manufacturing. The right format for a molecule depends on its chemical stability, clinical application, and the setting in which it will be administered. Liquid vials are sealed glass containers with rubber stoppers and aluminium crimp seals, available in single-dose and multi-dose configurations. They are the most commonly used injectable format and suit molecules that are chemically stable in aqueous solution — including Paracetamol, Heparin, Ondansetron, and Propofol. Multi-dose vials contain antimicrobial preservatives to maintain sterility after the first puncture. Glass ampoules are hermetically sealed single-dose glass containers that are broken open at point of use. The fused glass seal provides the highest sterility assurance of any injectable format — with no risk of stopper-related contamination or re-entry. Ampoules are preferred for single-use critical care molecules including Lidocaine, Ropivacaine, Labetalol, Dexamethasone, and Ketorolac. Dry powder injections contain the active pharmaceutical ingredient in sterile powder form, to be reconstituted with a specified diluent at point of use. This format is used for molecules that degrade in aqueous solution and cannot be manufactured or stored as a liquid — including Ceftriaxone, Pantoprazole, and Methylprednisolone. Dry powder filling requires additional facility capability including moisture-controlled aseptic filling environments and headspace gas analysis on every batch. 9M India manufactures all three formats from its sterile facility in Birkoni, Chhattisgarh.

Sterility in injectable manufacturing at 9M India is maintained through a multi-layer system of facility design, validated processes, continuous monitoring, and in-house analytical testing — not through a single control point. The aseptic fill-finish zone operates at Grade A (ISO Class 5) within a Grade B (ISO Class 7) background environment. This is the highest level of environmental control used in pharmaceutical manufacturing and is the standard required by WHO, EU GMP, and DCGI for sterile injectable production. Pressure differentials between cleanroom zones are continuously monitored. Personnel follow validated gowning procedures with documented compliance records. All sterilisation and aseptic processes are validated — meaning they have been demonstrated through documented studies to consistently achieve the required level of sterility assurance across the full range of batch sizes and process parameters. Validation is repeated periodically and after any process or equipment change. Environmental monitoring runs on a scheduled programme covering viable (microbiological) and non-viable (particulate) sampling of air, surfaces, equipment, and personnel — at frequencies defined by the validated monitoring programme. Every batch undergoes in-house sterility testing per USP <71>, bacterial endotoxin testing (LAL test) per USP <85>, particulate matter analysis per USP <788>, and container closure integrity testing before release. No batch is dispatched before the in-house QC laboratory issues a signed Certificate of Analysis confirming all tests are within specification.